Senti Biosciences is a technology company.
Senti Biosciences has raised $53.0M across 1 funding round.
Key people at Senti Biosciences.
Senti Biosciences has raised $53.0M in total across 1 funding round.
Key people at Senti Biosciences.
Senti Biosciences has raised $53.0M in total across 1 funding round.
Senti Biosciences's investors include Menlo Ventures, New Enterprise Associates, Omega Funds, Osage University Partners.
# Senti Biosciences: Engineering Smarter Medicines Through Synthetic Biology
Senti Biosciences is a clinical-stage biotechnology company, not a traditional technology company, though it leverages advanced synthetic biology as its core technology platform.[2][3] The company was founded to create a new generation of intelligent cell and gene therapies by programming cells with proprietary Gene Circuits—novel combinations of DNA sequences that enable cells to sense disease environments, make computational decisions, and respond with precision.[2][3]
Senti Bio serves patients with incurable diseases, primarily focusing on oncology indications.[3] The company's mission centers on developing therapeutics that can precisely kill cancer cells while sparing healthy ones, addressing a fundamental limitation of current cell therapy approaches.[2] Its lead product candidate, SENTI-202, is currently in clinical trials in the U.S. for acute myeloid leukemia (AML) treatment.[3]
Senti Bio's competitive advantages stem from its proprietary Gene Circuit platform, which represents a fundamental shift in how cell therapies are engineered:[1][2]
Senti Bio operates at the intersection of two transformative trends in medicine: synthetic biology and cell therapy innovation.[1][3] The synthetic biology field has evolved rapidly over recent decades, and Senti Bio positions itself as uniquely positioned to harness this potential for significant medical advances.[3]
The company addresses critical limitations in current cell therapy technologies by introducing programmable biological logic—a capability that distinguishes next-generation therapeutics from earlier approaches.[1] This positions Senti Bio within the rapidly evolving immuno-oncology and cell therapy landscape, where the ability to engineer precise, controllable, and intelligent therapeutics represents a significant competitive advantage.[1] The company has established key partnerships within the pharmaceutical sector, underscoring its strategic market presence.[1]
Senti Biosciences represents a meaningful advancement in how cell therapies can be engineered and controlled. As SENTI-202 progresses through clinical development for AML, the company's ability to demonstrate clinical efficacy with its Gene Circuit platform could validate synthetic biology as a transformative approach in oncology and potentially expand into autoimmune diseases.[1][2] The convergence of improved synthetic biology tools, growing clinical validation of cell therapies, and the company's proprietary technology positions Senti Bio to influence how next-generation cellular immunotherapies are developed across the industry. Success in the clinic would likely accelerate adoption of programmable cell therapy approaches more broadly, reshaping the competitive landscape of cell and gene therapy development.
Senti Biosciences has raised $53.0M across 1 funding round. Most recently, it raised $53.0M Series A in February 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2018 | $53.0M Series A | Menlo Ventures, New Enterprise Associates, Omega Funds, Osage University Partners |